ArticleCancer gene therapy2014
Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Article in Cancer gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma
A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.Cancer medicine · 2025Review
- Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma.Materials today. Bio · 2025Review
- Review
- Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024Review
- Silencing of the MEG3 gene promoted anti-cancer activity and drug sensitivity in glioma.Journal of cellular and molecular medicine · 2023Article
- Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy · 2023Review
- THOC2 expression and its impact on 5-fluorouracil resistance in glioblastoma multiforme.American journal of cancer research · 2023Article
- Radiosensitization to γ-Ray by Functional Inhibition of APOBEC3G.International journal of molecular sciences · 2022Article
- Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.Expert opinion on biological therapy · 2021Review
- Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II).Brain sciences · 2021Review
- Recent progress in the research of suicide gene therapy for malignant glioma.Neurosurgical review · 2021Review
- Clinically Explored Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma in Adults.Biomedicines · 2021Review
- Current Approaches for Glioma Gene Therapy and Virotherapy.Frontiers in molecular neuroscience · 2021Review
- Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma.Frontiers in oncology · 2021Review
- Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.Frontiers in pharmacology · 2021Review
- Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.Ecancermedicalscience · 2021Review
- Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers.Cancer cell international · 2020Article
- Article
- Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies.Nanomaterials (Basel, Switzerland) · 2019Review
- Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.